Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 126 clinical trials
Featured trial
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and …

  • 0 views
  • 17 May, 2022
  • 8 locations
Featured trial
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

  • 0 views
  • 16 May, 2022
  • 131 locations
Featured trial
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 0 views
  • 17 May, 2022
  • 101 locations
Featured trial
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

cell transplantation
myelofibrosis
  • 0 views
  • 18 May, 2022
  • 13 locations
Featured trial
Myelofibrosis

Myelofibrosis

  • 532 views
  • 08 Nov, 2020
  • 1 location
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera (MITHRIDATE)

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.

interferon
hydroxyurea
ruxolitinib
  • 1 views
  • 03 Mar, 2022
  • 2 locations
Serological Screen and Treat Trial for Plasmodium Vivax (SSAT)

This is a clinical trial to evaluate an experimental serological diagnostic technique intended to identify people at high risk of having dormant malaria parasites in their liver. The study is designed to evaluate the efficacy of serological screening vs. routine care for the prevention of recurrent P. vivax infections. A …

Accepts healthy volunteers
  • 0 views
  • 10 Mar, 2022
  • 1 location
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

ropeginterferon alfa-2b
interferon
thrombosis
thrombocytosis
neutrophil count
  • 0 views
  • 25 Mar, 2022
  • 57 locations
Extension Study After Completion of Phase 2 Study for P1101 With Polycythemia Vera (PV) Patients (Study A19-201)

This is an extension study after completion of Phase 2 single arm study to investigate efficacy and safety of P1101 for adult Japanese patients with PV.

  • 0 views
  • 18 Dec, 2021
  • 6 locations
Safety Evaluation Study for Patients With Polycythemia Vera

This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera

phlebotomy
  • 0 views
  • 22 Mar, 2022
  • 3 locations